chronic hepatitis C
Hepatology · 2005–2020
32decisions
19medicines
11carried consumer input
1,112individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| glecaprevir with pibrentasvir Treatment of chronic hepatitis C (CHC) infection in patients who are treatment-naïve with compensated cirrhosis, genotypes 1-6, with a shortened 8-week… | Dec 2020 | Recommended | none received |
| direct-acting antiviral (DAA) regimens Treatment of chronic hepatitis C virus (HCV) infection. The submission addresses changes to PBS listings and conditions for DAA regimens following a clinical… | Mar 2019 | Recommended | no section in document |
| This is a status report on the National Hepatitis C Data Collection (REACH-C study), which monitors the real-world cost-effectiveness and health outcomes of… | Mar 2019 | Noted | no section in document |
| sofosbuvir with velpatasvir and voxilaprevir Treatment of adult patients with chronic hepatitis C who have received prior treatment with an NS5A-based treatment regimen and not achieved sustained… | Mar 2018 | Recommended with restriction | input received Hepatitis Australia |
| glecaprevir with pibrentasvir Treatment of chronic hepatitis C (CHC) for genotypes 1-6 in adults aged 18 years or older, including treatment-naïve and treatment-experienced patients… | Jul 2017 | Deferred | input received |
| glecaprevir with pibrentasvir Chronic hepatitis C infection (CHC) for treatment naïve and treatment experienced patients (including those with prior NS5A treatment) with genotypes 1-6, with… | Nov 2017 | Recommended with restriction | input received |
| grazoprevir / elbasvir Treatment of chronic hepatitis C infection in patients infected with genotypes 1, 4 or 6 (irrespective of previous treatment history) and genotype 3… | Jul 2016 | Recommended with restriction | 6 individuals |
| ribavirin Extension of listing for chronic hepatitis C (CHC) treatment using daclatasvir + sofosbuvir + ribavirin regimens for HCV Genotypes 2, 3, 4, 5 and 6 in patients… | Jul 2016 | Recommended with restriction | none received |
| ribavirin Chronic hepatitis C infection (CHC) in adults, for use in combination therapy with other oral agents. The submission specifically concerned listing of an… | Jul 2016 | Recommended | none received |
| simeprevir Treatment of chronic hepatitis C infection in treatment naïve and treatment-experienced patients. | Mar 2016 | Recommended with restriction | no section in document |
| paritaprevir / ritonavir / ombitasvir / dasabuvir Treatment of patients with genotype 1 chronic hepatitis C infection who have compensated liver disease, irrespective of previous treatment history. | Jul 2015 | Recommended with restriction | 114 individuals |
| ribavirin Treatment of adults with chronic hepatitis C (CHC) genotype 2 or 3 in combination with sofosbuvir. The submission covers three distinct treatment populations:… | Jul 2015 | Deferred | 78 individuals |
| simeprevir Treatment of patients with genotype 1 chronic hepatitis C infection who have compensated liver disease, in combination with sofosbuvir, irrespective of… | Jul 2015 | Recommended with restriction | 78 individuals |
| asunaprevir Chronic genotype 1b hepatitis C virus (HCV) infection, administered in combination with daclatasvir, in patients with compensated liver disease. | Mar 2015 | Not recommended | 172 individuals Gastroenterological Society |
| ribavirin Treatment of chronic hepatitis C (CHC) genotypes 2 and 3 in treatment-naïve patients with compensated liver disease, in combination with sofosbuvir. | Mar 2015 | Not recommended | 172 individuals Gastroenterological Society |
| sofosbuvir Treatment of chronic hepatitis C (CHC) in treatment-naïve and treatment-experienced patients with genotypes 1-6, administered in combination with peginterferon… | Mar 2015 | Recommended with restriction | 231 individuals Gastroenterological Society |
| daclatasvir Treatment of chronic hepatitis C infection (CHC) across all genotypes (1-6), irrespective of previous treatment history or cirrhosis status, in patients with… | Nov 2015 | Recommended with restriction | none received |
| ribavirin Treatment of adults with chronic hepatitis C (CHC) genotype 2 or 3 in combination with direct-acting antivirals (DAAs), particularly sofosbuvir. | Nov 2015 | Recommended with restriction | no section in document |
| simeprevir Treatment of patients with genotype 1 chronic hepatitis C (CHC) infection who have compensated liver disease, in combination with sofosbuvir, irrespective of… | Nov 2015 | Recommended with restriction | no section in document |
| sofosbuvir Treatment of chronic hepatitis C (CHC) in multiple populations across genotypes 1-6, including treatment-naïve and treatment-experienced patients, with… | Jul 2014 | Not recommended | 261 individuals |
| boceprevir treatment of chronic hepatitis C in patients 18 years or older who have compensated liver disease and who are treatment naïve or who have failed one prior… | Mar 2012 | Recommended | unclear |
| telaprevir Treatment of genotype 1 chronic hepatitis C in adult patients with compensated liver disease, including cirrhosis, who are treatment naïve or have previously… | Mar 2012 | Recommended with restriction | unclear |
| boceprevir Treatment of chronic hepatitis C genotype 1 infection in combination with peginterferon alfa and ribavirin in patients 18 years or older with compensated liver… | Mar 2012 | Recommended with restriction | unclear |
| boceprevir and ribavirin and peginterferon alfa-2b treatment of chronic hepatitis C in treatment naïve and treatment experienced patients aged 18 years and older who meet certain criteria | Nov 2012 | Not recommended | no section in document |
| boceprevir Treatment, managed by an accredited treatment centre, of chronic hepatitis C in patients 18 years or older who have compensated liver disease and who are naïve… | Jul 2011 | Not recommended | unclear |
| ribavirin and peginterferon alfa-2b treatment of chronic hepatitis C in children and adolescents with a bodyweight of greater than or equal to 27 kg with compensated liver disease and who have… | Jul 2011 | Recommended with restriction | no section in document |
| peginterferon alfa-2a, ribavirin Treatment of chronic hepatitis C in patients who have failed one prior attempt at interferon based therapies (non-pegylated or pegylated). | Jul 2010 | Recommended with restriction | no section in document |
| peginterferon alfa-2a and ribavirin Treatment of chronic hepatitis C in patients 18 years or older who have compensated liver disease and have failed one prior attempt at interferon-based… | Jul 2010 | Recommended with restriction | no section in document |
| ribavirin treatment of chronic hepatitis C in patients who have failed one prior attempt at interferon alfa or peginterferon alfa treatment for hepatitis C and who… | Jul 2008 | Recommended | no section in document |
| ribavirin and peginterferon alfa-2b Treatment of chronic hepatitis C in patients who have failed one prior attempt at interferon-based therapy (non-pegylated or pegylated). | Jul 2008 | Recommended with restriction | no section in document |
| peginterferon alfa-2b treatment of chronic hepatitis C in patients who have not previously received interferon treatment, with or without ribavirin | Nov 2005 | Recommended with restriction | no section in document |
| peginterferon alfa-2b and ribavirin Treatment of chronic hepatitis C in patients with no or mild hepatitis C fibrosis, with removal of the liver biopsy requirement for eligibility determination. | Nov 2005 | Recommended with restriction | no section in document |
Who spoke
Gastroenterological Society · Hepatitis Australia
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 11 of 20 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.